The estimated Net Worth of Eric Curtis is at least $530 millier dollars as of 7 April 2021. Mr Curtis owns over 791 units of Windtree Therapeutics stock worth over $3,938 and over the last 4 years he sold WINT stock worth over $0. In addition, he makes $526,246 as Sr. VP & COO at Windtree Therapeutics.
Mr has made over 2 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 791 units of WINT stock worth $1,993 on 7 April 2021.
The largest trade he's ever made was buying 791 units of Windtree Therapeutics stock on 7 April 2021 worth over $1,993. On average, Mr trades about 184 units every 26 days since 2020. As of 7 April 2021 he still owns at least 1,291 units of Windtree Therapeutics stock.
You can see the complete history of Mr Curtis stock trades at the bottom of the page.
Eric L. Curtis M.B.A. is the Sr. VP & COO at Windtree Therapeutics.
As the Sr. VP & COO of Windtree Therapeutics, the total compensation of Mr A at Windtree Therapeutics is $526,246. There are 3 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of $1,063,640.
Mr A is 52, he's been the Sr. VP & COO of Windtree Therapeutics since . There are 14 older and no younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
Eric's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... et Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: